GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pet Pharm Biotech Co Ltd (ROCO:7762) » Definitions » EV-to-FCF

Pet Pharm Biotech Co (ROCO:7762) EV-to-FCF : -18.96 (As of Mar. 03, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Pet Pharm Biotech Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pet Pharm Biotech Co's Enterprise Value is NT$2,943.6 Mil. Pet Pharm Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-155.3 Mil. Therefore, Pet Pharm Biotech Co's EV-to-FCF for today is -18.96.

The historical rank and industry rank for Pet Pharm Biotech Co's EV-to-FCF or its related term are showing as below:

ROCO:7762' s EV-to-FCF Range Over the Past 10 Years
Min: -19.74   Med: 0   Max: 186.77
Current: -19.09

During the past 2 years, the highest EV-to-FCF of Pet Pharm Biotech Co was 186.77. The lowest was -19.74. And the median was 0.00.

ROCO:7762's EV-to-FCF is ranked worse than
100% of 547 companies
in the Drug Manufacturers industry
Industry Median: 23.07 vs ROCO:7762: -19.09

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-03), Pet Pharm Biotech Co's stock price is NT$61.60. Pet Pharm Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$0.218. Therefore, Pet Pharm Biotech Co's PE Ratio (TTM) for today is 282.57.


Pet Pharm Biotech Co EV-to-FCF Historical Data

The historical data trend for Pet Pharm Biotech Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pet Pharm Biotech Co EV-to-FCF Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23
EV-to-FCF
- -

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
EV-to-FCF - - - -

Competitive Comparison of Pet Pharm Biotech Co's EV-to-FCF

For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pet Pharm Biotech Co's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pet Pharm Biotech Co's EV-to-FCF falls into.



Pet Pharm Biotech Co EV-to-FCF Calculation

Pet Pharm Biotech Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2943.634/-155.257
=-18.96

Pet Pharm Biotech Co's current Enterprise Value is NT$2,943.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pet Pharm Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-155.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pet Pharm Biotech Co  (ROCO:7762) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Pet Pharm Biotech Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=61.60/0.218
=282.57

Pet Pharm Biotech Co's share price for today is NT$61.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pet Pharm Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$0.218.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pet Pharm Biotech Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pet Pharm Biotech Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pet Pharm Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.

Pet Pharm Biotech Co Headlines

No Headlines